Bing

Catalyst Pharmaceuticals (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, will visit the Nasdaq MarketSite in …
The Street · 8/18/2015
Since the company is heavily dependent on Firdapse for growth, any regulatory setback may affect the stock adversely.” CPRX has been the subject of several other reports. Roth Capital reaffirmed a buy rating and set …
Mideast Times · 8/18/2015
The stock’s 50-day moving average price is $4.61 and its 200 day moving average price is $4.15. The company’s market capitalization is $303.51 million. Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last posted its quarterly earnings data on …
Ticker Report · 8/27/2015
More from Bing News
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat.Com reports. One investment analyst has rated the stock with …
sleekmoney.com · 8/20/2015
As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of ...
4 Traders · 8/18/2015
I can show you much uglier charts of other smaller biotechs like Catalyst Pharmaceuticals (NASDAQ:CPRX), one of my core long holdings: (click to enlarge) Or look at this chart of Juno Therapeutics (NASDAQ:JUNO) …
Seeking Alpha · 8/21/2015
China